Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology
Armata Pharmaceuticals (NYSE American: ARMP) announced the publication of a research paper in the Journal of Molecular Biology detailing the structural analysis of phage Pa223, a component of their clinical candidate AP-PA02. The study provides the first structural description of a phage from the Bruynoghevirus genus using advanced cryogenic electron microscopy.
AP-PA02, a five-phage cocktail, is being developed to treat chronic respiratory infections in cystic fibrosis and non-cystic fibrosis bronchiectasis (NCFB) patients. The therapeutic has demonstrated promising results in two Phase 2 clinical trials - SWARM-P.a. and Tailwind. The structural insights gained from this research may inform future development of phage-based therapeutics.
Armata Pharmaceuticals (NYSE American: ARMP) ha annunciato la pubblicazione su Journal of Molecular Biology di uno studio che descrive l'analisi strutturale del fago Pa223, componente del suo candidato clinico AP-PA02. Lo studio offre la prima descrizione strutturale di un fago del genere Bruynoghevirus ottenuta mediante avanzata microscopia elettronica crio.
AP-PA02, un cocktail composto da cinque fagi, è in sviluppo per il trattamento delle infezioni respiratorie croniche in pazienti con fibrosi cistica e bronciectasie non correlate a fibrosi cistica (NCFB). Il farmaco ha mostrato risultati promettenti in due studi di Fase 2 - SWARM-P.a. e Tailwind. Le informazioni strutturali ricavate potrebbero guidare lo sviluppo futuro di terapie a base di fagi.
Armata Pharmaceuticals (NYSE American: ARMP) anunció la publicación en Journal of Molecular Biology de un artículo que detalla el análisis estructural del fago Pa223, componente de su candidato clínico AP-PA02. El estudio proporciona la primera descripción estructural de un fago del género Bruynoghevirus mediante microscopía electrónica criogénica avanzada.
AP-PA02, un cóctel de cinco fagos, se está desarrollando para tratar infecciones respiratorias crónicas en pacientes con fibrosis quística y bronquiectasias no asociadas a fibrosis quística (NCFB). El fármaco ha mostrado resultados prometedores en dos ensayos de Fase 2 – SWARM-P.a. y Tailwind. Los datos estructurales obtenidos podrían orientar el desarrollo futuro de terapias basadas en fagos.
Armata Pharmaceuticals (NYSE American: ARMP)는 Journal of Molecular Biology에 임상 후보물질 AP-PA02의 구성 성분인 파지 Pa223의 구조 분석을 다룬 연구 논문을 게재했다고 발표했습니다. 이 연구는 고급 극저온 전자현미경을 이용해 Bruynoghevirus 속 파지의 구조를 처음으로 규명한 것입니다.
AP-PA02는 다섯 종의 파지로 구성된 칵테일로, 낭포성 섬유증 및 비낭포성 섬유증 기관지확장증(NCFB) 환자의 만성 호흡기 감염 치료를 위해 개발 중입니다. 이 치료제는 두 건의 2상 임상시험인 SWARM-P.a.와 Tailwind에서 유망한 결과를 보였습니다. 이번 구조적 통찰은 향후 파지 기반 치료제 개발에 정보를 제공할 수 있습니다.
Armata Pharmaceuticals (NYSE American: ARMP) a annoncé la publication dans le Journal of Molecular Biology d'un article décrivant l'analyse structurale du phage Pa223, composant de son candidat clinique AP-PA02. L'étude fournit la première description structurale d'un phage du genre Bruynoghevirus obtenue par cryo-microscopie électronique avancée.
AP-PA02, un cocktail de cinq phages, est en développement pour traiter les infections respiratoires chroniques chez les patients atteints de mucoviscidose et de bronchectasie non liée à la mucoviscidose (NCFB). Le traitement a montré des résultats prometteurs dans deux essais de phase 2 - SWARM-P.a. et Tailwind. Les informations structurales obtenues pourraient orienter le développement futur de thérapeutiques à base de phages.
Armata Pharmaceuticals (NYSE American: ARMP) gab die Veröffentlichung einer Forschungsarbeit im Journal of Molecular Biology bekannt, die die strukturelle Analyse des Phagen Pa223 beschreibt, einem Bestandteil ihres klinischen Kandidaten AP-PA02. Die Studie liefert die erste strukturelle Beschreibung eines Phagen der Gattung Bruynoghevirus mittels hochauflösender kryoelektronenmikroskopie.
AP-PA02, ein Cocktail aus fünf Phagen, wird zur Behandlung chronischer Atemwegsinfektionen bei Patienten mit zystischer Fibrose und nicht-zystischer-fibrotischer Bronchiektasie (NCFB) entwickelt. Das Therapeutikum zeigte vielversprechende Ergebnisse in zwei Phase‑2-Studien – SWARM‑P.a. und Tailwind. Die gewonnenen strukturellen Erkenntnisse könnten die zukünftige Entwicklung phagenbasierter Therapeutika unterstützen.
- AP-PA02 has shown promising results in two Phase 2 clinical trials
- Pa223 phage demonstrates broad host range and high lytic activity against both planktonic and biofilm-associated bacteria
- Research breakthrough provides valuable structural insights for future phage therapy development
- None.
Insights
Armata's structural analysis of phage Pa223 enhances scientific understanding while supporting ongoing clinical development of their promising anti-Pseudomonas therapy.
The publication in the Journal of Molecular Biology marks a significant scientific milestone for Armata Pharmaceuticals by providing the first structural description of a Bruynoghevirus genus phage used in experimental therapy. This research on phage Pa223, a component of Armata's five-phage cocktail AP-PA02, offers valuable insights into the structural characteristics that may influence clinical effectiveness against Pseudomonas infections.
This scientific advancement is particularly noteworthy as AP-PA02 has already demonstrated promising results in two Phase 2 clinical trials - SWARM-P.a. and Tailwind - targeting chronic respiratory infections in cystic fibrosis and non-cystic fibrosis bronchiectasis patients. The high-resolution structural analysis using cryo-EM technology has created what the researchers call a "structural atlas" of Pa223, potentially accelerating phage therapeutic development.
The research collaboration between Armata and academic partners, including Dr. Gino Cingolani at The University of Alabama at Birmingham, demonstrates the company's commitment to advancing fundamental phage biology while pursuing clinical applications. This dual approach of basic science research alongside clinical development strengthens Armata's scientific foundation in the competitive bacteriophage therapeutics space.
For a clinical-stage biotechnology company focused on antibiotic-resistant infections, this type of fundamental research enhances understanding of their therapeutic candidates while potentially informing future development strategies. The structural insights gained from this work could have broader implications for other phages in clinical cocktails, potentially expanding Armata's therapeutic applications beyond current indications.
Describes the structure of phage Pa223, which is included in Armata's multi-phage anti-Pseudomonas clinical candidate, AP-PA02
The publication, titled, "High-resolution Cryo-EM Analysis of the Therapeutic Pseudomonas Phage Pa223," describes the structure of phage Pa223, which is included in Armata's five-phage clinical cocktail, AP-PA02. Armata is developing AP-PA02 as a potential treatment for chronic respiratory infections in people with cystic fibrosis and non-cystic fibrosis bronchiectasis (NCFB). AP-PA02 has shown promising results in two Phase 2 clinical trials to date - SWARM-P.a. and Tailwind.
"The ability to collaborate with brilliant bench scientists and clinical partners simultaneously at universities and medical centers is critically important," stated Dr. Deborah Birx, Chief Executive Officer of Armata, and co-author of the paper. "With this latest scientific research, we further advanced our collective understanding of fundamental phage biology, specifically, how structural characteristics may impact clinical utility against a dangerous bacterial pathogen. This groundbreaking structural analysis may be beneficial in informing future development plans to bring further innovation to patients suffering from serious bacterial infections."
Dr. Gino Cingolani, Anderson Family Endowed Chair in Medical Education, Research & Patient Care and Professor in the Department of Biochemistry and Molecular Genetics, The University of
The full paper can be found here.
About Armata Pharmaceuticals, Inc.
Armata is a clinical-stage biotechnology company focused on the development of high-purity pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other important pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage-specific current Good Manufacturing Practices ("cGMP") manufacturing to support full commercialization.
Forward Looking Statements
This communication contains "forward-looking" statements as defined by the Private Securities Litigation Reform Act of 1995. These statements relate to future events, results or to Armata's future financial performance and involve known and unknown risks, uncertainties and other factors which may cause Armata's actual results, performance or events to be materially different from any future results, performance or events expressed or implied by the forward-looking statements. In some cases, you can identify these statements by terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of those terms, and similar expressions. These forward-looking statements reflect management's beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this communication and are subject to risks and uncertainties including risks related to Armata's development of bacteriophage-based therapies; ability to staff and maintain its production facilities under fully compliant cGMP; ability to meet anticipated milestones in the development and testing of the relevant product; ability to be a leader in the development of phage-based therapeutics; ability to achieve its vision, including improvements through engineering and success of clinical trials; ability to successfully complete preclinical and clinical development of, and obtain regulatory approval of its product candidates and commercialize any approved products on its expected timeframes or at all; and Armata's estimates regarding anticipated operating losses, capital requirements and needs for additional funds. Additional risks and uncertainties relating to Armata and its business can be found under the caption "Risk Factors" and elsewhere in Armata's filings and reports with the
Armata expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Armata's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Media Contacts:
At Armata:
Pierre Kyme
ir@armatapharma.com
310-665-2928
Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
212-915-2569
View original content to download multimedia:https://www.prnewswire.com/news-releases/armata-pharmaceuticals-announces-structural-biology-publication-in-the-journal-of-molecular-biology-302547710.html
SOURCE Armata Pharmaceuticals, Inc.
FAQ
What is the significance of Armata's (ARMP) new publication in the Journal of Molecular Biology?
What is Armata Pharmaceuticals' AP-PA02 being developed for?
How many phages are included in Armata's AP-PA02 clinical cocktail?
What clinical trials has Armata's AP-PA02 completed?
What are the key characteristics of the Pa223 phage in Armata's therapeutic?
